During his 46-year term running Yuyu Pharma, Dr. Yu transformed Yuyu’s product portfolio from one focusing on generic drugs to one focusing on specialty drugs. In anticipation of an aging society, Dr. Yu oversaw the introduction of two new improved drugs: Maxmarvil, for the treatment of osteoporosis and Yuclid, an antiplatelet drug. During his tenure, Yuyu Pharma, while small, had grown into a shiny diamond-like company.
In addition, from 2001, Dr. Yu served as the fourth Chairman of the Korean Pharmaceutical Bio Association (KPBA), representing the voice of the pharmaceutical industry and helped to establish the separation of the prescription and dispensing of pharmaceuticals, thereby striving to create the conditions for the sustainable development of Korea’s pharmaceutical industry. In recognition of his efforts to improve public health as Chairman of the KPBA, Dr. Yu was awarded the Order of Merit in 2003.
Dr. Yu has also served as the honorary consul of the Republic of Haiti since 1997 and served as the Honorary Consul General of Korea for four years from 2013 making great efforts for communication and harmonization among honorary consuls who play an important role in elevating the status of the Republic of Korea. Furthermore, Dr. Yu is also the honorary Chairman of the Korean National Opera (KNO), practicing the policy of returning corporate profits back to the community through its patronage of the KNO.
After retirement, Dr. Yu will serve as honorary Chairman to Yuyu Pharma, continue to promote the culture and arts at Heyri Village, and continue to mentor young students at universities.
SOURCE Yuyu Pharma
